{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:25:57Z","timestamp":1790832357294,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T00:00:00Z","timestamp":1673740800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecules and Cells"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.14348\/molcells.2023.2172","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T21:27:56Z","timestamp":1674682076000},"page":"10-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1876-3359","authenticated-orcid":false,"given":"Young Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9024-9501","authenticated-orcid":false,"given":"Adrian R.","family":"Krainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14348\/molcells.2023.2172_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/nat.2020.0845","article-title":"The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy","volume":"30","author":"Aartsma-Rus","year":"2020","journal-title":"Nucleic Acid Ther."},{"key":"10.14348\/molcells.2023.2172_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","article-title":"Therapeutic antisense oligonucleotides are coming of age","volume":"70","author":"Bennett","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.14348\/molcells.2023.2172_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.14348\/molcells.2023.2172_bib4","unstructured":"CFTR1 (Cystic Fibrosis Mutation Database) (2022). CFMDB Statistics. Retrieved October 22, 2022, from http:\/\/www.genet.sickkids.on.ca\/StatisticsPage.html"},{"key":"10.14348\/molcells.2023.2172_bib5","unstructured":"CFTR2 (Clinical and Functional TRanslation of CFTR) (2022). CFTR2 Variant List History. Retrieved April 29, 2022, from https:\/\/cftr2.org\/sites\/default\/files\/CFTR2_29April2022.xlsx"},{"key":"10.14348\/molcells.2023.2172_bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1006\/geno.1998.5517","article-title":"The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C\u2192T mutation","volume":"53","author":"Chiba-Falek","year":"1998","journal-title":"Genomics"},{"key":"10.14348\/molcells.2023.2172_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1165\/rcmb.2006-0173OC","article-title":"No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations","volume":"37","author":"Clancy","year":"2007","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.14348\/molcells.2023.2172_bib8","first-page":"326","article-title":"The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis","volume":"40","author":"Clarke","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.14348\/molcells.2023.2172_bib9","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","author":"Crooke","year":"2007"},{"key":"10.14348\/molcells.2023.2172_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: an overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.14348\/molcells.2023.2172_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jcf.2017.05.003","article-title":"Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice","volume":"16","author":"Crosby","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"10.14348\/molcells.2023.2172_bib12","unstructured":"Cystic Fibrosis Foundation (2021). 2020 Patient Registry Annual Data Report. Retrieved September 15, 2021, from https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/2019-Patient-Registry-Annual-Data-Report.pdf"},{"key":"10.14348\/molcells.2023.2172_bib13","unstructured":"Cystic Fibrosis Foundation (2022). Drug Development Pipeline. Retrieved October 23, 2022, from https:\/\/apps.cff.org\/trials\/pipeline\/"},{"key":"10.14348\/molcells.2023.2172_bib14","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1093\/nar\/gkab488","article-title":"Enhanced delivery of peptide-morpholino oligonucleotides with a small molecule to correct splicing defects in the lung","volume":"49","author":"Dang","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.14348\/molcells.2023.2172_bib15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"Darras","year":"2019","journal-title":"CNS Drugs"},{"key":"10.14348\/molcells.2023.2172_bib16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.14348\/molcells.2023.2172_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.14348\/molcells.2023.2172_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcf.2019.05.014","article-title":"Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis","volume":"19","author":"Drevinek","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.14348\/molcells.2023.2172_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jcf.2020.02.006","article-title":"Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA","volume":"19","author":"Dukovski","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.14348\/molcells.2023.2172_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"10.14348\/molcells.2023.2172_bib21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.14348\/molcells.2023.2172_bib22","doi-asserted-by":"crossref","first-page":"36193","DOI":"10.1074\/jbc.274.51.36193","article-title":"Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides","volume":"274","author":"Friedman","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.14348\/molcells.2023.2172_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2472555217729790","article-title":"Use of a high-throughput phenotypic screening strategy to identify amplifiers, a novel pharmacological class of small molecules that exhibit functional synergy with potentiators and correctors","volume":"23","author":"Giuliano","year":"2018","journal-title":"SLAS Discov."},{"key":"10.14348\/molcells.2023.2172_bib24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1074\/jbc.M116.764720","article-title":"Correctors and potentiators rescue function of the truncated W1282X-cystic fibrosis transmembrane regulator (CFTR) translation product","volume":"292","author":"Haggie","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.14348\/molcells.2023.2172_bib25","doi-asserted-by":"crossref","first-page":"R264","DOI":"10.1093\/hmg\/ddab191","article-title":"Human Molecular Genetics and the long road to treating cystic fibrosis","volume":"30","author":"Harris","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.14348\/molcells.2023.2172_bib26","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.14348\/molcells.2023.2172_bib27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13059-017-1386-9","article-title":"Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations","volume":"19","author":"Huang","year":"2018","journal-title":"Genome Biol."},{"key":"10.14348\/molcells.2023.2172_bib28","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.14348\/molcells.2023.2172_bib29","doi-asserted-by":"crossref","first-page":"e60478","DOI":"10.1371\/journal.pone.0060478","article-title":"Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression","volume":"8","author":"Keeling","year":"2013","journal-title":"PLoS One"},{"key":"10.14348\/molcells.2023.2172_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1165\/rcmb.2018-0316OC","article-title":"Nonsense-mediated RNA decay pathway inhibition restores expression and function of W1282X CFTR","volume":"61","author":"Keenan","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.14348\/molcells.2023.2172_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.mcp.0000141247.22078.46","article-title":"Pharmacologic therapy for stop mutations: how much CFTR activity is enough?","volume":"10","author":"Kerem","year":"2004","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.14348\/molcells.2023.2172_bib32","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/13543784.2020.1828862","article-title":"ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease","volume":"29","author":"Kerem","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.14348\/molcells.2023.2172_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.14348\/molcells.2023.2172_bib34","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1038\/s41467-022-30668-y","article-title":"Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"key":"10.14348\/molcells.2023.2172_bib35","article-title":"Exon-skipping antisense oligonucleotides for cystic fibrosis therapy","volume":"119","author":"Kim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.14348\/molcells.2023.2172_bib36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","article-title":"Quality and quantity control of gene expression by nonsense-mediated mRNA decay","volume":"20","author":"Kurosaki","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.14348\/molcells.2023.2172_bib37","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.14348\/molcells.2023.2172_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1021\/mp400230s","article-title":"Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay","volume":"11","author":"Lentini","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.14348\/molcells.2023.2172_bib39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.14348\/molcells.2023.2172_bib40","first-page":"7454","article-title":"Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells","volume":"48","author":"Michaels","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.14348\/molcells.2023.2172_bib41","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114886119","article-title":"Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis","volume":"119","author":"Michaels","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.14348\/molcells.2023.2172_bib42","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.14348\/molcells.2023.2172_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2016.10.009","article-title":"Clinical potential of oligonucleotide-based therapeutics in the respiratory system","volume":"169","author":"Moschos","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"10.14348\/molcells.2023.2172_bib44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2016.09.005","article-title":"Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation","volume":"16","author":"Mutyam","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"10.14348\/molcells.2023.2172_bib45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nbt.3427","article-title":"Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decay","volume":"34","author":"Nomakuchi","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.14348\/molcells.2023.2172_bib46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jcf.2021.12.012","article-title":"Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation","volume":"21","author":"Oren","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.14348\/molcells.2023.2172_bib47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jcf.2021.06.003","article-title":"Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation","volume":"20","author":"Oren","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.14348\/molcells.2023.2172_bib48","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/sj.gt.3302994","article-title":"Expression of CFTR from a ciliated cell-specific promoter is ineffective at correcting nasal potential difference in CF mice","volume":"14","author":"Ostrowski","year":"2007","journal-title":"Gene Ther."},{"key":"10.14348\/molcells.2023.2172_bib49","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/acn3.51149","article-title":"Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: a systematic review","volume":"7","author":"Pascual-Morena","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.14348\/molcells.2023.2172_bib50","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/JEP.S255377","article-title":"Pharmacological modulation of ion channels for the treatment of cystic fibrosis","volume":"13","author":"Pinto","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.14348\/molcells.2023.2172_bib51","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.14348\/molcells.2023.2172_bib52","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.14348\/molcells.2023.2172_bib53","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/s41467-022-29935-9","article-title":"CFTR mRNAs with nonsense codons are degraded by the SMG6-mediated endonucleolytic decay pathway","volume":"13","author":"Sanderlin","year":"2022","journal-title":"Nat. Commun."},{"key":"10.14348\/molcells.2023.2172_bib54","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ymthe.2019.06.016","article-title":"Steric inhibition of 5\u2032 UTR regulatory elements results in upregulation of human CFTR","volume":"27","author":"Sasaki","year":"2019","journal-title":"Mol. Ther."},{"key":"10.14348\/molcells.2023.2172_bib55","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/nar\/gkz1132","article-title":"Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides","volume":"48","author":"Scharner","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.14348\/molcells.2023.2172_bib56","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1038\/s41467-021-24575-x","article-title":"A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat. Commun."},{"key":"10.14348\/molcells.2023.2172_bib57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-4939-7374-3_10","article-title":"Designing effective antisense oligonucleotides for exon skipping","volume":"1687","author":"Shimo","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.14348\/molcells.2023.2172_bib58","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.14348\/molcells.2023.2172_bib59","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"10.14348\/molcells.2023.2172_bib60","first-page":"CD010966","article-title":"Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)","volume":"12","author":"Southern","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.14348\/molcells.2023.2172_bib61","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/oli.1.2000.10.359","article-title":"Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice","volume":"10","author":"Templin","year":"2000","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.14348\/molcells.2023.2172_bib62","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jcf.2018.12.001","article-title":"Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells","volume":"18","author":"Valley","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"10.14348\/molcells.2023.2172_bib63","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.14348\/molcells.2023.2172_bib64","first-page":"2068","article-title":"Patients with cystic fibrosis have new triple-drug combination","volume":"322","author":"Voelker","year":"2019","journal-title":"JAMA"},{"key":"10.14348\/molcells.2023.2172_bib65","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.6b00551","article-title":"The medicinal chemistry of therapeutic oligonucleotides","volume":"59","author":"Wan","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.14348\/molcells.2023.2172_bib66","doi-asserted-by":"crossref","first-page":"e0152232","DOI":"10.1371\/journal.pone.0152232","article-title":"Robust stimulation of W1282X-CFTR channel activity by a combination of allosteric modulators","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.14348\/molcells.2023.2172_bib67","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4155\/tde.13.47","article-title":"Oligonucleotide conjugates for therapeutic applications","volume":"4","author":"Winkler","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.14348\/molcells.2023.2172_bib68","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.14348\/molcells.2023.2172_bib69","first-page":"e16144","article-title":"A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"key":"10.14348\/molcells.2023.2172_bib70","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1080\/14656566.2017.1359255","article-title":"Ataluren in cystic fibrosis: development, clinical studies and where are we now?","volume":"18","author":"Zainal Abidin","year":"2017","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Molecules and Cells"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pdf.medrang.co.kr\/KSMCB\/2023\/046\/KSMCB046-01-04.pdf","content-type":"unspecified","content-version":"tdm","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1016847823000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1016847823000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/pdf.medrang.co.kr\/KSMCB\/2023\/046\/KSMCB046-01-04.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T17:55:17Z","timestamp":1760896517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1016847823000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1016847823000043"],"URL":"https:\/\/doi.org\/10.14348\/molcells.2023.2172","relation":{},"ISSN":["1016-8478"],"issn-type":[{"value":"1016-8478","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives","name":"articletitle","label":"Article Title"},{"value":"Molecules and Cells","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14348\/molcells.2023.2172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 THE AUTHORS. Published by Elsevier Inc on behalf of the Korean Society for Molecular and Cellular Biology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}